When to Say No: A Physician's Responsibility

Physician responsibility includes saying no. In longevity and peptide medicine — a field with real promise, uneven evidence and heavy marketing — the willingness to decline a request is one of the clearest signs that a clinician is putting the patient's safety ahead of a sale. In my practice, a no is never the end of the conversation; it comes with a reason and, almost always, a better path.

Why Physician Responsibility Includes "No"

Cash-pay and concierge medicine change the business model, not the ethics. Patients pay for time, access and a physician's full attention. They do not pay for a guaranteed prescription. If anything, the absence of an insurance gatekeeper places more responsibility on the physician to be the one who asks: is this indicated, is it safe, and is the evidence good enough for this person?

Optimization medicine also carries a particular temptation. Many requests come from motivated, well-read patients who have seen a compound praised online. Saying yes is easy and pleasant. Saying no requires explanation, and occasionally disappointment. But the duty is the same as in any other area of internal medicine: first, do no harm.

Situations Where I Say No

These are not exhaustive, and every decision is individual. But certain scenarios consistently lead to a no — or a not yet.

Active or recent cancer with growth-signaling compounds

Agents that stimulate growth hormone, IGF-1 or blood-vessel growth raise a theoretical concern in people with active cancer or a recent history of it. The data to quantify that risk do not exist. I will not take an unquantified risk on a patient's behalf when the expected benefit is modest.

Pregnancy, breastfeeding or trying to conceive

Most peptides have no human safety data in pregnancy. That alone is reason enough.

Unexplained symptoms without a diagnosis

Fatigue, weight gain, low libido and poor sleep have many causes, including thyroid disease, anemia, sleep apnea, depression and medication effects. A peptide that masks a symptom can delay a diagnosis. The answer here is "not yet" — evaluation first.

Uncontrolled cardiovascular risk

For example, compounds that raise blood pressure, such as bremelanotide, are not appropriate with uncontrolled hypertension or known heart disease. Fix the foundation before adding risk.

Products not made for human use

I do not prescribe, source or supervise "research peptides" bought online, and I do not help patients self-inject them. These products lack verified identity, purity and sterility. Requests for compounds that are not authorized for compounding — such as BPC-157 while FDA rulemaking is still pending — are met with an honest explanation of current status rather than a workaround.

Compounds with poor risk-benefit profiles

Some substances — SARMs such as LGD-4033, for example — were never approved, carry documented risks, and are banned in sport. Others, like MK-677, raise blood sugar and were not recommended for compounding by FDA's advisory committee. I decline these.

Competitive athletes

Many peptides and hormone-modulating agents are prohibited by anti-doping rules. Athletes subject to testing deserve a clear warning, not a prescription that could end a career.

How I Say No

Declining well is a skill. My approach:

1. Explain the reason in plain language — the specific risk, the state of the evidence or the regulatory issue.
2. Acknowledge the goal. The underlying wish — more energy, better recovery, healthier aging — is legitimate.
3. Offer an alternative. Often there is a better-supported path to the same goal: treating sleep apnea, a structured training plan, an FDA-approved medication, or a further workup.
4. Define what would change the answer. "If your blood pressure is controlled for three months, we can revisit this" is more useful than a flat refusal.
5. Document and follow up, so the decision is part of an ongoing plan.

What Saying No Is Not

Saying no is not paternalism or a refusal to engage with new science. I discuss investigational compounds openly, including what is promising, what is unproven and what is unknown. It is also not a judgment of the patient. Wanting to feel and function better is reasonable. And it is not permanent — evidence and regulations change, and so do individual circumstances.

It is also worth recognizing that some reported benefits of optimization therapies reflect expectation effects. That does not make patients' experiences less real, but it does mean that strong feelings about a compound are not the same as evidence. I discuss this further in Understanding Placebo in Optimization Medicine.

What You Should Expect From a Responsible Clinic

Whether you see me or anyone else, look for these signs:

• A full history, medication review and labs before any therapy.
• Clear statements of FDA status and the strength of evidence.
• No sourcing from "research" suppliers.
• Willingness to say "I don't know," "not yet" or "no."
• A plan for monitoring and an agreed point at which to stop.

More on this in Why Physician Supervision Matters Before Considering Peptides.

The Bottom Line

Physician responsibility in longevity medicine means offering access to promising therapies when they are appropriate — and declining when they are not. At Laeeq M.D., every no comes with an explanation, an alternative and a path forward. That is what evidence-aware care looks like.

Book a Consultation

If you want an honest, physician-led assessment of what is likely to help you — and what is not — Dr. Laeeq offers a 60-minute consultation, virtually or in person in Reston, VA. Book a consultation for an evaluation grounded in your history, labs and goals.

This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.